Rociletinib regulatory update

FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 12-1 that FDA should await the outcome of the confirmatory Phase III TIGER-3 trial of rociletinib from Clovis before the agency decides whether to approve the lung cancer therapy. Clovis is seeking accelerated approval of

Read the full 427 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE